Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.39 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18994724 | 0.82 | GAA (0.67) | GAAOPRM1CYP3A4CYP2D6KDM4E | |
| SCHEMBL21081224 | 0.82 | SIGMAR1 (0.47) | SIGMAR1GAAOPRM1CYP3A4CYP2D6 | |
| SCHEMBL21173102 | 0.82 | SIGMAR1 (0.47) | SIGMAR1GAAOPRM1CYP3A4CYP2D6 | |
| SCHEMBL21600567 | 0.80 | SIGMAR1 (0.39) | SIGMAR1GAAOPRM1CYP3A4CYP2D6 | |
| SCHEMBL19791308 | 0.78 | GAA (0.41) | GAAOPRM1CYP3A4CYP2D6KDM4E | |
| SCHEMBL24538638 | 0.77 | GAA (0.72) | SIGMAR1GAAOPRM1CYP3A4CYP2D6 | |
| SCHEMBL19199626 | 0.77 | GAA (0.72) | SIGMAR1GAAOPRM1CYP3A4CYP2D6 | |
| SCHEMBL18229424 | 0.77 | GAA (0.72) | SIGMAR1GAAOPRM1CYP3A4CYP2D6 | |
| SCHEMBL16444908 | 0.77 | GAA (0.72) | SIGMAR1GAAOPRM1CYP3A4CYP2D6 | |
| SCHEMBL21095062 | 0.75 | GRIN1 (0.62) | SIGMAR1OPRM1CYP3A4CYP2D6MRGPRX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752592-B2 | Morphan and morphinan analogues, and methods of use | ALKERMES PHARMA IRELAND LIMITED (IE) | 2020-08-25 | — | — | US | disclosed |
| US-10736890-B2 | Methods for treating depressive symptoms | ALKERMES PHARMA IRELAND LIMITED (IE) | 2020-08-11 | — | — | US | disclosed |
| US-20190218185-A1 | Morphan And Morphinan Analogues, And Methods Of Use | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2019-07-18 | — | — | US | disclosed |
| US-20190167666-A1 | METHODS FOR TREATING DEPRESSIVE SYMPTOMS | ALKERMES PHARMA IRELAND LIMITED (IE) | 2019-06-06 | — | — | US | disclosed |
| US-10231963-B2 | Methods for treating depressive symptoms | ALKERMES PHARMA IRELAND LIMITED (IE) | 2019-03-19 | — | — | US | disclosed |
| US-20170216279-A1 | METHODS FOR TREATING DEPRESSIVE SYMPTOMS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2017-08-03 | — | — | US | disclosed |
| US-9656961-B2 | Methods for treating depressive symptoms | ALKERMES PHARMA IRELAND LIMITED (IE) | 2017-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190167666-A1 | METHODS FOR TREATING DEPRESSIVE SYMPTOMS | OPRM1, OPRL1, OPRK1 | SIGMAR1 6/4885GAA 1347/4885OPRM1 1/4885 |
| US-10231963-B2 | Methods for treating depressive symptoms | OPRM1, OPRL1, OPRK1 | SIGMAR1 6/4885GAA 1347/4885OPRM1 1/4885 |
| US-10736890-B2 | Methods for treating depressive symptoms | OPRM1, OPRL1, OPRK1 | SIGMAR1 6/4885GAA 1347/4885OPRM1 1/4885 |
| US-10752592-B2 | Morphan and morphinan analogues, and methods of use | MTPN, UTRN, FSCN1 | SIGMAR1 1138/4885GAA 398/4885OPRM1 159/4885 |
| US-20170216279-A1 | METHODS FOR TREATING DEPRESSIVE SYMPTOMS | OPRM1, OPRL1, OPRK1 | SIGMAR1 6/4885GAA 1347/4885OPRM1 1/4885 |
| US-20190218185-A1 | Morphan And Morphinan Analogues, And Methods Of Use | MTPN, UTRN, FSCN1 | SIGMAR1 1138/4885GAA 398/4885OPRM1 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.